Live feed
·
PRReleasevia Quantisnow
Vistagen Therapeutics Inc. logo

Vistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

ByQuantisnow·Wall Street's wire, on your screen.
VTGN· Vistagen Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTGN (Vistagen Therapeutics Inc.) and more on Quantisnow.